Zofran: Clinical Trials

14 trials of Zofran, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed, 1 active not recruiting, 1 recruiting, 1 terminated. 14 Phase 3, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 314Completed 10, Active not recruiting 1, Recruiting 1, Terminated 1, Withdrawn 1
Phase 24Completed 1, Recruiting 1, Terminated 1, Withdrawn 1

Follow Zofran: new trials by email Literature Review of Zofran trials Research Report on Zofran

Trials (filtered) newest first · largest first

All 14 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
The Efficacy of B6 and Metoclopramide Combination in Comparison With the Other Antiemetics
Metoclopramide and Vitamin B6, Vitamin B6, Ondansetron - Vomiting
Phase 2 / Phase 3CompletedUniversity of Baghdad2502024-01-302024-04-30
Ondansetron and Gabapentin in Preventing Postoperative Nausea and Vomiting After Laparoscopic Sleeve Gastrectomy
Ondansetron 8mg, Gabapentin - Post Operative Nausea and Vomiting, Sleeve Gastrectomy
Phase 3CompletedTanta University1002022-10-012025-04-17
Inhaled Isopropyl Alcohol for Treatment of Nausea
Inhaled Isopropyl Alcohol, Oral Ondansetron, Inhaled Placebo - Vomiting, Nausea
Phase 2 / Phase 3RecruitingState University of New York at Buffalo842022-04-202026-09-24
Cisplatin Disposition and Kidney Injury
Granisetron, Ondansetron, Palonosetron - Nephrotoxicity
Phase 3Active not recruitingUniversity of Colorado, Denver452019-11-152026-09-17
Multi-DOSE Oral Ondansetron for Pediatric Acute GastroEnteritis
Ondansetron Oral Solution, Oral Placebo - Acute Gastroenteritis, Viral Illness
Phase 3CompletedUniversity of Calgary10302019-09-142025-04-25
Triage Administration of Ondansetron for Gastroenteritis in Children
Ondansetron, Placebos - Gastroenteritis
Phase 2 / Phase 3TerminatedSt. Justine's Hospital812017-07-152020-10-22
Transversus Abdominis Plane Block in Microsurgical Breast Recon w/Abdominal Free Flap in Breast CA
Transversus Abdominis Plane (TAP) block, Nimbus Infusion Pump IV Administration, Bupivacaine infusion - Breast - Female
Phase 3CompletedStanford University1202015-11-012021-09-23
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)
Fosaprepitant dimeglumine, Fosaprepitant Placebo, Dexamethasone - Chemotherapy-Induced Nausea and Vomiting (CINV)
Phase 3CompletedMerck Sharp & Dohme LLC10152012-09-242018-09-04
Pharmacogenetic Treatments for Alcoholism
Ondansetron + Brief Behavioral Enhancement Treatment, Placebo + Brief Behavioral Enhancement Treatment - Alcoholism
Phase 2 / Phase 3WithdrawnUniversity of Virginia2012-06-012023-04-20
Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation
Granisetron, Ondansetron, Questionnaires - Cancer of the Cervix
Phase 3CompletedM.D. Anderson Cancer Center762012-03-012021-06-11
Symptomatic Treatment of Acute Gastroenteritis
Ondansetron, Domperidone, placebo - Gastroenteritis, Vomiting
Phase 3CompletedIRCCS Burlo Garofolo3562011-07-012014-04-21
Combined Pharmacotherapies for Alcoholism
Ondansetron 4 ug/kg b.i.d. + Cognitive Behavioral Therapy, Naltrexone 50 mg/day + Cognitive Behavioral Therapy, Ondansetron 4 ug/kg b.i.d.+ Naltrexone 50 mg/day + Cognitive Behavioral Therapy - Alcoholism
Phase 3CompletedBankole Johnson3002008-09-012013-03-15
Pharmacological Treatment for Alcoholism
Ondansetron + Cognitive Behavioral Therapy, Placebo + Cognitive Behavioral Therapy - Alcohol Dependence
Phase 3CompletedBankole Johnson2832006-06-012012-02-07
A Study to Examine the Safety and Tolerability of MK0517 for the Prevention of Post-Operative Nausea and Vomiting (0517-015)
Comparator: MK0517, Comparator: ondansetron - Post-Operative Nausea and Vomiting
Phase 3CompletedMerck Sharp & Dohme LLC2162005-07-012015-08-19

Conditions studied

Vomiting (8)  ·  Alcoholism (3)  ·  Gastroenteritis (3)  ·  Nausea (2)  ·  Diarrhea (1)  ·  Emergencies (1)  ·  Obesity, Morbid (1)  ·  Postoperative Nausea and Vomiting (1)  ·  Uterine Cervical Neoplasms (1)  ·  Virus Diseases (1)

Sponsors

Bankole Johnson (2)  ·  Merck Sharp & Dohme LLC (2)  ·  IRCCS Burlo Garofolo (1)  ·  M.D. Anderson Cancer Center (1)  ·  St. Justine's Hospital (1)  ·  Stanford University (1)  ·  State University of New York at Buffalo (1)  ·  Tanta University (1)  ·  University of Baghdad (1)  ·  University of Calgary (1)  ·  University of Colorado, Denver (1)  ·  University of Virginia (1)

Countries

United States (7)  ·  Canada (2)  ·  Egypt (1)  ·  Iraq (1)  ·  Italy (1)

Top investigators

Alana Koehler, MD (1)  ·  Bankole Johnson, DSc, MD, PhD (1)  ·  Bankole Johnson, DSc,MD,PhD (1)  ·  Bankole Johnson, M.D., Ph.D. (1)  ·  Edgar Jaimes, MD (1)  ·  Federico Marchetti, MD (1)  ·  Gordon K Lee, MD (1)  ·  Hashim Talib T Hashim, MBChB (1)  ·  Heather Territo, MD (1)  ·  Jocelyn Gravel, MD (1)  ·  Maurizio Bonati, MD (1)  ·  Melanie Joy, PharmD, PhD (1)  ·  Michael M. Frumovitz, MD, MPH (1)

Results publications

PMID 23897038, PMID 26449391, PMID 29808377, PMID 32460879, PMID 32838813, PMID 32988373, PMID 38955285, PMID 39711135, PMID 39726772, PMID 40673584, PMID 42090154, PMID 42637866, PMID 42782131

NIH funding

R01AA010522 (1), R01AA012964 (1), R01GM123330 (1)